Valuation: TaiMed Biologics Inc.

Market Cap 15.68B 481M 430M 396M 359M 671M 45.63B 683M 4.72B 1.9B 24B 1.8B 1.77B 75.7B P/E 2026 *
-74.5x
P/E 2027 * -53.6x
Enterprise Value 15.8B 484M 434M 399M 361M 676M 45.98B 688M 4.76B 1.91B 24.19B 1.82B 1.78B 76.27B EV / Sales 2026 *
24.3x
EV / Sales 2027 * 24.4x
Free-Float
66.62%
Yield 2026 *
-
Yield 2027 * -
10-21 TaiMed Biologics Reports IDWeek 2026 Data Highlighting TMB-365 And Its Potential Across Long-Acting HIV Combinations CI
08-12 TaiMed Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-08 TaiMed Biologics Gets Taiwanese Drug Regulator's Approval for HIV Therapy Trogarzo MT
07-07 TaiMed Biologics Receives TFDA Drug License Collection Notice For Trogarzo And Advances TMB-365/380 Clinical Development CI
07-05 TaiMed Biologics Receives TFDA Drug License Collection Notice For Trogarzo And Announces Commercial Launch In Taiwan CI
05-21 TaiMed Biologics Inc. Completes Phase 2b Enrollment For TMB-365/380 In HIV Maintenance Therapy Study CI
05-13 TaiMed Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-08 TaiMed Biologics Inc. announced a financing transaction CI
03-12 TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
12-16 TaiMed Biologics Announces First-Patient-In for Its World-First Long-Acting Dual Antibody HIV Therapy TMB-365/TMB-380 Phase 2b Trial CI
11-12 TaiMed Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-08-12 TaiMed Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-06-22 TaiMed Biologics Inc. Initiates Phase 2b Clinical Study Preparation of Bi-Monthly Dosing of TMB-365/TMB-380 Combination for the Treatment of HIV Infection CI
1 day-4.33%
1 week-6.06%
Current month-9.89%
1 month-8.89%
3 months+1.59%
6 months+16.19%
Current year-6.21%
1 week 57.4
Extreme 57.4
61.6
1 month 57.4
Extreme 57.4
63.9
Current year 47
Extreme 47
75.4
1 year 47
Extreme 47
75.4
3 years 47
Extreme 47
116.5
5 years 47
Extreme 47
135
10 years 47
Extreme 47
349.5
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 2008-05-31
General Counsel - -
Director TitleAgeSince
Chairman - -
Director/Board Member 64 2017-05-25
Director/Board Member 68 2018-09-06
Change 5-day change 1-year change 3-year change Capi.($)
-4.33%-6.06% - - 503M
Average -4.33%
Weighted average by Cap. -4.33%

Financials

2026 *2027 *
Net sales 650M 19.92M 17.84M 16.41M 14.87M 27.79M 1.89B 28.31M 196M 78.56M 995M 74.76M 73.17M 3.14B 650M 19.92M 17.84M 16.41M 14.87M 27.79M 1.89B 28.31M 196M 78.56M 995M 74.76M 73.17M 3.14B
Net income -209M -6.41M -5.74M -5.28M -4.78M -8.94M -608M -9.1M -62.92M -25.26M -320M -24.04M -23.53M -1.01B -293M -8.98M -8.04M -7.4M -6.7M -12.53M -853M -12.76M -88.21M -35.41M -448M -33.7M -32.98M -1.41B
Net Debt 119M 3.65M 3.27M 3M 2.72M 5.09M 346M 5.18M 35.83M 14.38M 182M 13.69M 13.4M 574M 153M 4.69M 4.2M 3.86M 3.5M 6.54M 445M 6.66M 46.06M 18.49M 234M 17.6M 17.22M 739M
Projected Income Statement - Annual - TaiMed Biologics Inc.
Logo TaiMed Biologics Inc.
TaiMed Biologics Inc is a Taiwan-based company primarily engaged in the research and development of new drugs. The Company provides Trogarzo (TMB-355) for the treatment of Acquired Immune Deficiency Syndrome (AIDS). The Company's Trogarzo is a biweekly, long-acting monoclonal antibody drug primarily for multi-drug resistant patients with AIDS. The product is available in intravenous drip, intravenous push, and intramuscular dosage forms. The Company sells its products internationally.
Employees
-
Date Price Change Volume
26-10-29 NT$57.40 -4.33% 1,054,189
26-10-29 NT$60.00 -0.50% 306,852
26-10-28 NT$60.30 -1.15% 445,973
26-10-27 NT$61.00 -0.16% 402,967
26-10-22 NT$61.10 -2.24% 1,082,134
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
BB
MarketScreener Ratings - TaiMed Biologics Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
57.40TWD
Average target price
180.00TWD
Spread / Average Target
+213.59%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - TaiMed Biologics Inc.
  1. Stock Market
  2. Stocks
  3. 4147 Stock